Muraglitazar NEW
| Price | $293 | $719 | $987 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-15 |
Product Details
| Product Name: Muraglitazar | CAS No.: 331741-94-7 |
| Purity: 99.31% | Supply Ability: 10g |
| Release date: 2026/05/15 |
Product Introduction
Bioactivity
| Name | Muraglitazar |
| Description | Muraglitazar (BMS-298585) is a dual agonist of PPARα/γ that exerts metabolic regulatory effects including lipid modulation, glucose reduction, improvement of insulin resistance, and weight loss. It is indicated for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar exhibits potent in vitro activity against human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM). |
| In vitro | Methods: Steatotic HepaRG cells were treated with 50 μM Muraglitazar for 24 hours or 14 days. After incubation with [1?C]-palmitic acid, β-oxidation products were detected to assess fatty acid oxidation (FAO) activity, and mRNA expression of lipid metabolism and nuclear receptor-related genes was analyzed by RT-qPCR. Results: Short-term treatment with Muraglitazar had no effect on FAO. After 14 days of treatment, Muraglitazar significantly increased FAO activity, downregulated de novo lipogenesis genes, and persistently upregulated FAO-related genes. Additionally, Muraglitazar upregulated the expression of FXR and CAR nuclear receptors, further inhibiting lipid synthesis.[4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (6.39 mM), Sonication is recommended. DMSO : 128.8 mg/mL (249.35 mM), Sonication is recommended. |
| Keywords | Muraglitazar | human PPARγ | hPPARα | BMS298585 | BMS 298585 |
| Inhibitors Related | PHYTOL | Rosiglitazone | Retinoic acid | Daidzein | Fenofibrate | Magnesium acetate tetrahydrate | Maltitol | Naringenin | 2,3-Butanediol | NPC 15199 | Icariin | Cloxiquine |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Failed Clinical Trials Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Diabetic Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2580.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY